Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Posted on by Pencis

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Union Hospital, Tongii Medical | China

Author Profile

Scopus

Orcid id

🏥 Dr. Jianjun Xu: Pioneering Hepatobiliary Oncology Specialist

👨‍⚕️ Full Name: Jianjun Xu

🏅 Designation: Attending Doctor

🏨 Department:

  • Department of Hepatobiliary Surgery
  • Center for Liver Transplantation

🎓 Qualification: Doctor

🔬 Area of Specialization: Hepatobiliary Oncology and Cancer

💡 Sub Division: Oncology Therapeutics and Novel Approaches

🕒 Total Experience:

  • Work for 2 years
  • Doctor for 3 years
  • Master for 3 years
  • Bachelor for 5 years

 

🎓 Education

📚 2011-2016: Bachelor of Clinical Medicine, School of Medicine, Nanchang University.

🎓 2016-2019: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏫 2019-2022: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏥 Experience

🩺 July 2022 to Present: Attending Doctor at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, China.

🔬 Contributions to Research, Innovations, and Extension Activities On Hepatobiliary Oncology and Cancer

Throughout his tenure, Dr. Jianjun Xu has made significant contributions to Tumor Research & Development, Innovations, and Extension Activities. Actively participating in research projects, he has advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. Leveraging his expertise in hepatobiliary malignancies, Dr. Xu collaborates with interdisciplinary teams to identify novel biomarkers, therapeutic targets, and treatment modalities, aiming to improve patient outcomes and quality of life.

Dr. Xu has also been involved in innovative initiatives to translate research findings into clinical practice. By fostering partnerships with industry stakeholders, academic institutions, and healthcare providers, he has facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

In addition to his research endeavors, Dr. Xu actively engages in extension activities to disseminate knowledge and promote awareness of cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the necessary information and resources to combat cancer effectively. His dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

NOTABLE PUBLICATION:

Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma

Citation: 52        Year: 2021

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

Citation: 18        Year: 2022

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy

Citation: 09        Year: 2021

Laparoscopic resection of hepatic epithelioid hemangioendothelioma: report of eleven rare cases and literature review

Citation: 05        Year: 2020

Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma

Citation: 02        Year: 2023

Prof Dr.Ronny Priefer – Cancer Biomarkers – Best Researcher Award

Posted on by Pencis

Prof Dr.Ronny Priefer - Cancer Biomarkers - Best Researcher Award

MCPHS University - United States

AUTHOR PROFILE

Scopus 

Orcid

EARLY ACADEMIC PURSUITS

Ronny Prieger's academic journey began with a Bachelor of Science degree in Chemistry from the University of Northern British Columbia. He then pursued his passion for organic chemistry, earning a Ph.D. from McGill University in Montreal, Quebec. His early academic pursuits laid a solid foundation for his future endeavors in the field of medicinal chemistry.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Ronny Prieger joined Neurochem Inc. in Saint-Laurent, Quebec, Canada, as a Post-Doctoral Fellow. This position provided him with valuable industry experience and exposure to neurochemistry research.Subsequently, Prieger transitioned into academia, where he served as an Associate Dean of Graduate Studies at the School of Pharmacy, Massachusetts College of Pharmacy and Health Science University (MCPHS) in Boston. He also held the position of Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences at MCPHS, further solidifying his role in academia.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Throughout his career, Ronny Prieger has made significant contributions to the field of medicinal chemistry. His research focus spans various areas, including neurochemistry, cancer biomarkers and organic chemistry. Prieger's work has contributed to advancing our understanding of drug development and neurodegenerative diseases.

IMPACT AND INFLUENCE

Prieger's contributions have had a notable impact on both academia and industry. His research findings have been instrumental in shaping the direction of medicinal chemistry research, particularly in the development of novel therapeutics for neurological disorders.

ACADEMIC CITATIONS

Ronny Prieger's research has garnered attention within the academic community, as evidenced by the numerous citations his work has received in scholarly publications. His contributions to the field have been recognized and cited by peers and colleagues, further solidifying his reputation as a respected researcher in medicinal chemistry.

LEGACY AND FUTURE CONTRIBUTIONS

As an established figure in the field of medicinal chemistry, Ronny Prieger's legacy extends beyond his current endeavors. His dedication to research and education has inspired future generations of scientists and pharmaceutical professionals. Moving forward, Prieger continues to make significant contributions to the field, with a focus on advancing drug discovery and improving treatments for neurological disorders.

NOTABLE PUBLICATIONS

Layer-by-layer assembly: A versatile approach for tailored biomedical films and drug delivery. 2024

A comparison of continuous glucose monitors (CGMs) in diabetes management: A systematic literature review. 2023

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma. 2023

Challenges Related to Extractables/Leachables During Bioprocessing. 2023

Detection technologies of volatile organic compounds in the breath for cancer diagnoses. 2023 (4)

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023